Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 104Active not recruiting 66Completed 35Not yet recruiting 25Terminated 9Withdrawn 3Suspended 2Enrolling by invitation 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2

Interventions

Specimen Handling 33Magnetic Resonance Spectroscopy 21Biopsy 19Cyclophosphamide 10venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Vincristine 5Etoposide 5Bevacizumab 5fludarabine phosphate 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Injections 4Doxorubicin 4Cisplatin 4fludarabine 3durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Leucovorin 3Irinotecan 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × 130-nm albumin-bound paclitaxel × 1 year × Clear all
NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03417921 2025-10-01

Pancreatic

Ability Pharmaceuticals SL

Phase 1/2 Suspended
60 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡